Neumiller Joshua J, Odegard Peggy Soule, White John R, Setter Stephen M, Campbell R Keith
The Department of Pharmacotherapy, Washington State University/Elder Services, Spokane, Washington (JJN, SMS)
School of Pharmacy, University of Washington, Seattle (PSO)
Diabetes Educ. 2008 Mar-Apr;34(2):183-200. doi: 10.1177/0145721708316620.
Strong evidence exists demonstrating the benefits of tight glycemic control in type 1 and type 2 diabetes mellitus patients, but glycemic goals are not adequately achieved for many patients. Advancement in the knowledge surrounding the physiology of endogenous glucoregulatory peptide hormones, such as glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1, has led to new therapeutic targets for the treatment of type 2 diabetes mellitus. Dipeptidyl peptidase-4 (DPP-4) inhibitors provide practitioners with a novel mechanism of action to use for combination therapies for the treatment of type 2 diabetes mellitus. This article, part 3 of a 3-part series, reviews the new class of medications known as DPP-4 inhibitors as well as discusses a future buccal insulin formulation, Oral-Lyn, on the horizon for the treatment of diabetes mellitus.
有强有力的证据表明，严格控制血糖对1型和2型糖尿病患者有益，但许多患者并未充分实现血糖目标。围绕内源性葡萄糖调节肽激素（如葡萄糖依赖性促胰岛素多肽和胰高血糖素样肽-1）生理学的知识进展，为2型糖尿病的治疗带来了新的治疗靶点。二肽基肽酶-4（DPP-4）抑制剂为从业者提供了一种用于2型糖尿病联合治疗的新作用机制。本文是一个3部分系列的第3部分，回顾了被称为DPP-4抑制剂的新型药物类别，并讨论了即将用于糖尿病治疗的未来颊用胰岛素制剂Oral-Lyn。
